标普和纳斯达克内在价值 联系我们

Biofrontera Inc. BFRIW NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
32/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Biofrontera Inc. (BFRIW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.

分析师预估 每股收益(EPS)为 $-3.04 和 营收为 $0.04B (下一财年).

每股收益(EPS)历史表现: 2024: 实际 $0.00 vs 预期 $-3.04 (超预期 +99.9%). 2025: 实际 $-1.04 vs 预期 $-1.39 (超预期 +25.2%). 分析师准确度: 0%.

EPS 预测 — BFRIW

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$0.00 vs Est –$3.04 ▲ 94,743.8% off
2025 Actual –$1.04 vs Est –$1.39 ▲ 33.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.

营收预测 — BFRIW

96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.037B vs Est $0.039B ▼ 5.4% off
2025 Actual $0.042B vs Est $0.041B ▲ 2.3% off
Revenue Trend
Moderate revenue growth trend. Analysts expect stable revenue going forward.
联系我们
🎓
SharesGrow 学院
学习如何计算内在价值,发现被低估的股票。
每周在线课程
给我们留言